Navigation Links
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
Date:12/10/2008

BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combination with standard-of-care Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in treatment-naive patients chronically infected with the hepatitis C virus (HCV) genotype 1. ITMN-191 is being developed in collaboration with Roche.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We now expect to report top-line data from six dosage cohorts; three cohorts each of twice-daily and three-times-daily regimens. Although the 14-day triple combination study remains blinded at this time, and thus only limited inferences regarding safety can be made, adverse events to date have generally been mild to moderate and there have been no discontinuations during the study. Results from this study have guided the design of our planned Phase 2 program which is anticipated to begin in the first half of 2009."

Mr. Welch continued, "In addition, we are pleased to report that the first dosage cohort has been enrolled in the INFORM-1 study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ever study to investigate the combined effects of two direct antiviral agents in the absence of interferon in treatment-naive HCV patients. We expect results of this study to be reported at a major medical conference in the first half of 2009."

Phase 1b Triple Combination Trial Design

The Phase 1b randomized, double-blind, placebo-controlled, 14-day triple combination study in treatment-naive patients chronically infected with HCV genotype 1 was designed to inform the dose selection and study de
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ... reported financial results for the second quarter and three and ... are expressed in Canadian dollars and in accordance with International ... ESSA recorded a net loss of $5.9 million ... 31, 2015 (Q2-2015), compared to a net loss of $0.4 ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
(Date:5/28/2015)... MELVILLE, N.Y. , May 28, 2015 /PRNewswire/ ... ), the world,s largest provider of health care ... and medical practitioners, today reminded its customers that ... for dentists, physicians and veterinarians who experience operational, ... the disastrous storms in the South Central region ...
Breaking Medicine Technology:Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3
... Aug. 8, 2011 Symphony Corporation, a global ... of JGI, a New Jersey-based Human Capital Management ... in the healthcare industry nationally.  Symphony,s acquisition of ... to provide the highest level of benefits to ...
... 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... James P. Tursi has been promoted to Chief Medical ... Executive Officer and President of Auxilium, and sit on ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO) Dr. Tursi has been ...
Cached Medicine Technology:Symphony Corporation Acquires JGI to Provide End-to-End Services for Healthcare IT 2Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer 2Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer 3
(Date:5/29/2015)... NY (PRWEB) May 29, 2015 The world ... from old movies depicted dentists as sadists who dispense pain ... the dentist chair. What's more, when it came to surgeries, ... the dentist chair ­ but that's all back in the ... Leonard Umanoff's dental practice in the Sheepshead Bay ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
(Date:5/29/2015)... 2015 The FCPX Colorist brings professional color ... can adjust curves, hue, saturation and color levels like never ... , Each FCPX Colorist Tool installs into ... Final Cut Pro X Effects library. This modular set-up allows ... footage to achieve endless looks. , FCPX Colorist introduces curve ...
(Date:5/29/2015)... BETHESDA, MARYLAND (PRWEB) May 29, 2015 ... changes in the management of medical data. , Today ... on Electronic Health Records (EHR). The “ Report ... Status and Future Direction of EHRs ” was released ... (JAMIA) jamia.org and represents an evolutionary ...
(Date:5/29/2015)... Thursday, May 21st was the inaugural Red Nose Day in ... came together to raise money for kids living in poverty. ... to raising money for children and young people living in ... people at Hands-On Seminars decided to host their own event ... fun and laughter to their visitors, while raising awareness of ...
Breaking Medicine News(10 mins):Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 2Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 3Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 4Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3Health News:Announcing the Release of FCPX Colorist from Pixel Film Studios for Final Cut Pro X. 2Health News:AMIA Issues Report on Electronic Health Records - EHR-2020 2Health News:AMIA Issues Report on Electronic Health Records - EHR-2020 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2
... Proceeds from Private Placement of,Restricted Stock and Warrants ... CEDAR KNOLLS, N.J., Jan. 29 MedeFile,International, ... in,portable electronic medical records management solutions, today announced,that ... million from three,separate private placement transactions., Specifically, ...
... Jan. 29 HealthAware, a leading supplier of,innovative ... of,WeightAware, the newest disease module in its Cardiovascular ... obesity and,arthritis. The program targets only those who ... 12 months., WeightAware is an extension of ...
... percent to $23 billion -- Diluted earnings per share from continuing ... operations ... -- Full year Non-GAAP EPS now expected ... three-year, multi-billon-dollar Walgreens contract, DUBLIN, Ohio, Jan. 29 Cardinal Health, ...
... ... an increase of 15% reported (10% constant currency), -- ... -- Diluted EPS were $1.12 reported, an increase of 10% over the prior year ... prior year period, Zimmer Holdings, Inc. (NYSE: ZMH ...
... patients do the,research necessary to achieve the best results, ... consumers are stepping onto new car lots and into ... to results of the,American College of Surgeons, (ACS) latest ... an operation, patients are significantly less,proactive in learning about ...
... LEAWOOD, Kan., Jan. 29 The American Academy,of Family ... Union,address signaled his interest in improving access to health ... debate about health system reform., Improving Americans, ability ... in,helping create a health system that provides care to ...
Cached Medicine News:Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 2Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 3Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 4Health News:HealthAware Introduces Its WeightAware Cardiovascular Disease Module 2Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 2Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 4Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 5Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 6Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 7Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 8Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 9Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 10Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 11Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 12Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 13Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 14Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 15Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 16Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 17Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 18Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 19Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 20Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 21Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 22Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 23Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 24Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 25Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 26Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 4Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 5Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 6Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: